Figures & data
Figure 1. Well-differentiated neuroendocrine carcinoma of the pancreas (A), with liver metastases (B) (original magnification 400×).
![Figure 1. Well-differentiated neuroendocrine carcinoma of the pancreas (A), with liver metastases (B) (original magnification 400×).](/cms/asset/5eb02405-39e6-4b71-9e5a-9c429285176f/iups_a_707254_f0001_b.jpg)
Figure 2. PET scan performed at the end of the fourth cycle of peptide receptor-targeted radionuclide therapy with 177Lu-DOTATATE (A). Gross section of surgical specimens with a circular dark area in the endocervix (yellow arrow) (B).
![Figure 2. PET scan performed at the end of the fourth cycle of peptide receptor-targeted radionuclide therapy with 177Lu-DOTATATE (A). Gross section of surgical specimens with a circular dark area in the endocervix (yellow arrow) (B).](/cms/asset/01df4a0b-3e8a-4381-9abe-d90615aa35da/iups_a_707254_f0002_b.jpg)
Figure 3. Liquid-based cervical cytology demonstrating atypical cellular clusters (A, B) positive for chromogranin A (B) (original magnification 400×). Histological preparation of the cervix revealing poorly differentiated small cell neuroendocrine tumor involving the cervical crypts (C, D), positive for chromogranin A (C) (original magnification 400×).
![Figure 3. Liquid-based cervical cytology demonstrating atypical cellular clusters (A, B) positive for chromogranin A (B) (original magnification 400×). Histological preparation of the cervix revealing poorly differentiated small cell neuroendocrine tumor involving the cervical crypts (C, D), positive for chromogranin A (C) (original magnification 400×).](/cms/asset/82ae0a16-1cfc-404c-b501-4ff9ea317c4c/iups_a_707254_f0003_b.jpg)